5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Soňa Vodenková, Tomáš Büchler, Klára Červená, Veronika Veškrňová, Pavel Vodička, Veronika Vymetálková
Pharmacology & Therapeutics, 2019
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
Related Research
- The future of precision medicine: towards a more predictive personalized medicine 2020
- Detecting Personalized Determinants During Drug Treatment from Omics Big Data 2018
- Precision (personalized) medicine 2023
- TRANSFORMING HEALTHCARE WITH PRECISION MEDICINE: UNVEILING THE FUTURE OF PERSONALIZED TREATMENT 2023
- HARNESSING THE POWER OF PERSONALIZED MEDICINES: STEPS AND INNOVATIONS 2024
References
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer 2015
- DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. 2007
- MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer 2015
- THE CATABOLISM OF URACIL IN VIVO AND IN VITRO 1954
- Effects of 5-fluorouracil and 6-azauracil on the synthesis of ribonucleic acid and protein in <i>Saccharomyces carlsbergensis</i> 1968